Jun 1, 2021
- Updated outlook reflects lower recent and projected demand for COVID-19 tests
- Revised forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis
- Abbott's base business, excluding COVID-19 testing-related sales, continues to achieve strong growth
- R&D pipeline continues to be highly productive, with a steady cadence of recent and upcoming product launches across the portfolio